AHA video: Critics take high aim at AIM-HIGH; Boden responds
AHA: AIM-HIGH - 30.15 Mb
William E. Boden, MD, principal investigator of AIM-HIGH, spoke with Cardiovascular Business about the findings of his 2011 AHA late-breaking clinical trial. Source: University of Buffalo
ORLANDO, Fla.—AIM-HIGH, a late-breaking clinical trial presented at this year’s American Heart Association (AHA) scientific sessions, received a great deal of criticism for its design from its discussant, Philip Barter, MD, PhD; however, lead investigator William E. Boden, MD, strongly defended the design, even though he acknowledged to Cardiovascular Business that the results of the prematurely stopped trial will not change practice.

In May, the National Heart, Lung and Blood Institute stopped AIM-HIGH (co-sponsored by Abbott Laboratories), which was studying a blood lipid treatment, 18 months earlier than planned. However, Boden parsed out some of that discontinuation, including that the physicians involved learned about the trial's cessation a day after the decision. He also explained use of niacin in his clinical practice.

This video was conducted collaboratively with ClinicalTrialResults.org.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup